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Abstract
Introduction. An implantable cardioverter-defibrillator (ICD) with or without resynchronisation therapy (CRT-D) is an 
effective treatment in heart failure patients (pts.).
Materials and methods. We retrospectively analysed 60 patients (50/60; 83.33% male) with implanted ICD or CRT-D 
followed-up in the Cardiology Department between May 1995 and February 2019 who had undergone at least one 
device exchange.
Results. Women rarely received ICD, and especially ICD with CRT-D, compared to men [9/26 females in ICD and 1/24 
in CRT-D group (p = 0.035) OR 8.31 95% CI (0.98–70.56)] and presented higher left ventricular ejection fraction (LVEF) 
(38.11 ± 12.74% vs. 29.65 ± 12.63, p = 0.027). CRT-D in our patients was implanted mainly as primary prevention 
[22/25 vs. 18/35 (p = 0.0726) OR 6.93 95% CI (1.75–27.43)] and in patients with a lower LVEF compared to the ICD- 
-only patients [24.75 ± 8.98 vs. 35.52 ± 13.55% (p = 0.001)]. Technical analysis of endocardial lead parameters at im-
plantation and at the final follow-up revealed a decrease in impedance in cases of atrial, defibrillator and left-ventricular 
leads. In the ICD-only group, atrial impedance was 280.03 ± 335.3 vs. 218.29 ± 229.48 ohm (p = 0.0018), and defi-
brillator lead impedance was 768.66 ± 210.62 vs. 507.03 ± 131.67 ohm (p < 0.001) (at implantation vs. final follow-up 
respectively). In the ICD plus CRT-D group, mean atrial lead impedance was 511.05 ± 271.30 vs. 388.55 ± 231.75 ohm 
(p = 0.007), impedance of the defibrillator lead was 698.95 ± 165.45 vs. 547.13 ± 385.24 ohm (p = 0.002), and impe-
dance of the left-ventricular lead was 1,036.28 ± 337.34 vs. 794.87 ± 274.99 ohm (p < 0.001).
Conclusion. Women receive CRT-D therapy less often than men. CRT-D is implanted in pts. with lower LVEF and mainly 
as primary prevention. All endocardial leads impedance decreased with the passing of time.
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Introduction
Heart failure (HF) is a disease caused by cardiac 
dysfunction that is associated with high mortality. Among 
adults in developed countries, the prevalence of HF is 
about 1–2%. It is higher in older patients (pts.), reaching 
almost 10% among people aged above 70 years [1]. HF 
can be divided according to left ventricular ejection fraction 
(LVEF) into reduced ejection fraction (HFrEF) and preserved 
ejection fraction (HFpEF) [2]. It is important to note that 
different underlying aetiologies, demographics, and co-
-morbidities and varying responses to therapies are related 
to the degree of reduction of LVEF. Patients with HFpEF 
are older, more often female, and are less likely to have 
coronary artery disease compared to HFrEF pts [3, 4]. The 
treatment of HF has changed over the last 30 years, with 
nowadays implantable electronic devices and resynchroni-
sation therapy more often being used [5–7]. Based on the 
current guideline criteria for a cardiovascular implantable 
electronic device (CIED), only 5–10% of pts with HF are 
indicated for CRT therapy and approximately 70% of them 
are responders. Wider QRS, left bundle branch block, non-
-ischaemic cardiomyopathy, and female gender are factors 
associated with a better response to CRT [8].
Despite the improvements in HF treatment, the disease 
is still associated with a poor prognosis. 20% of patients 
admitted to hospital due to HF die within the first year, and 
approximately 50% die within five years of diagnosis. Saxon 
et al. analysed the survival status in patients implanted 
with ICD and CRT devices from a single manufacturer 
across the United States. One- and five-year survival rates 
in 185,778 patients after ICD implantation were 92% and 
68% respectively, and were 88% and 54% for CRT-D device 
recipients [9].
Endocardial lead problems may appear in the course of 
CIED therapy. Electrical integrity concerning electrical im-
pedance is calculated by measuring the voltage (V) and the 
current (I) and by applying Ohm’s law (R = V/I). The circuit 
comprises the connection between the generator’s header 
and the lead, the conductors to the tip and ring electrodes, 
and the electrode-myocardial interface. The most common 
causes of lead failure are insulation break and conductor 
fractures. The aim of our study was to analyse the long-term 
follow-up in patients with ICD and CRT-D therapy.
Material and methods
60 patients (male 50/60; 83.33%) with implanted ICD 
or CRT-D who had been followed-up in the Cardiology De-
partment between May 1995 and February 2019 who had 
undergone one or more device exchange due to the end of 
battery life were retrospectively analysed. ICD and CRT-D 
had been implanted according to the prevailing guidelines 
[5, 8]. ICD had been implanted in 35/60; 58.33% pts. (male 
26/35; 74.29%) and ICD plus CRT-D in 25/60; 41.66% 
pts. (male 24/25; 96%). In the medical histories, coronary 
artery disease had been diagnosed in 41 (68.33%) pts., 
chronic heart failure in 56 (93.3%) pts., hypertension in 
36 (60%) pts., atrial fibrillation in 36 (60%) pts., diabetes 
mellitus in 19 (31.67%) pts., chronic renal disease in 33 
(55%) pts., and previous stroke in seven (11.67%) pts. The 
clinical characteristics of the patients are set out in Table 1.
Statistical analysis
All data were expressed as mean numbers with stan-
dard deviation (± SD). The variables were analysed with chi-
-square, Yates chi-square, Fisher exact tests, Shapiro-Wilk, 
Mann-Whitney and t-Student tests. P-value < 0.05 was 
Table 1. Clinical characteristics of patients with implantable cardioverter-defibrillator (ICD) and patients with cardiac resynchronisation 
therapy with defibrillation (CRT-D)
Clinical characteristics Patients with CRT-D therapy Patients with ICD therapy p value
Number of patients 25 35 p > 0.05
Male 24/25 26/35 p > 0.05
Age at first implantation 60.36 ± 10.54 60.51 ± 14.07 p > 0.05
Age at final intervention (replacement/up-grade) 66.08 ± 10.31 68.43 ± 13.87 p > 0.05
Chronic kidney failure 18 (72%) 15 (42.86%) p > 0.05
Heart failure 25 (100%) 31 (88.57%) p > 0.05
Hypertension 15 (60%) 21 (60%) p > 0.05
Coronary artery disease 18 (72%) 23 (65.71%) p > 0.05
Atrial fibrillation 17 (68%) 19 (54.29%) p > 0.05
Diabetes mellitus 9 (36%) 10 (28.57%) p > 0.05
History of stroke 4 (16%) 3 (8.57%) p > 0.05
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identified as statistically significant. Predictive values were 
calculated and 95% confidence intervals for odds ratios 
were presented.
Results
The 60 patients who had undergone  ICD/CRT-D implan-
tation were at a similar age at the time of implantation. 
Most of them had coronary artery disease, hypertension, 
and/or atrial fibrillation (Table 2). The mean dwell time of 
CIED therapy was 86.55 ± 36.11 months. Male patients 
were predominant. There were 9/26 females in the ICD 
group and 1/24 females in the CRT-D group (p = 0.035) OR 
8.31 95% CI (0.98–70.56). Women presented with higher 
left ventricular ejection fraction compared to men 38.11 ± 
± 12.74% vs. 29.65 ± 12.63 (p = 0.027). Patients with 
CRT-D when compared to those with ICD presented lower 
LVEF 24.75 ± 8.98 vs. 35.52 ± 13.55% (p = 0.001). CRT-D 
was mainly implanted as primary prevention 22/25 vs. 
18/35 (p = 0.0726) OR 6.93 95% CI (1.75–27.43). Endo-
cardial lead impedance in cases of atrial, defibrillator and 
left-ventricular leads were lower at the final follow-up com-
pared to the values at implantation in both the ICD group 
and the CRT-D group (Table 3). In the ICD group, atrial impe-
dance was 280.03 ± 335.3 vs. 218.29 ± 229.48 ohm (p = 
= 0.0018), defibrillator lead impedance was 768.66 ± 
± 210.62 vs. 507.03 ± 131.67 ohm (p < 0.001) (at im-
plantation vs. final follow-up respectively). In the CRT-D 
group, the mean atrial lead impedance was 511.05 ± 
± 271.30 vs. 388.55 ± 231.75 ohm (p = 0.007), impedance 
of the defibrillator lead was 698.95 ± 165.45 vs. 547.13 ± 
± 385.24 ohm (p = 0.002), and impedance of the left-ventri-
cular lead was 1,036.28 ± 337.34 vs. 794.87 ± 274.99 ohm 
(p < 0.001) at implantation vs. final follow-up respectively.
Discussion
8,467 ICD and 4,164 CRT devices were implanted in Poland 
in 2016 [10]. Implantable electronic devices for heart failu-
re prolong a patient’s life and, in cases of CRT-D, improve 
the quality of life. In our study, we took into consideration 
the clinical presentation of patients and endocardial lead 
technical parameters at implantation and at the final 
follow-up. Our main observation was gender-related. Wo-
men rarely receive ICD, and especially CRT-D, compared 
to men, and women present with higher LVEF. CRT-D in our 
patients was implanted mainly as primary prevention and 
in pts. with lower LVEF compared to ICD. Technical analysis 
of endocardial lead parameters at implantation and at final 
follow-up revealed a decrease in impedance in cases of 
atrial, defibrillator and left-ventricular leads.
Large ICD therapy-related trials such as MADIT, MADIT 
II, SCD-HeFT, MUSTT, and DEFINITE AVID have involved 
between 8% and 29% of women, while CRT trials  such as 
MADIT-CRT and MIRACLE have contained a higher number 
of female patients (around 30%) [11–17]. In the MADIT 
trial, women were noted to have more advanced HF, as 
well as a higher incidence of hypertension, diabetes and 
Table 2. Lead-associated electrical parameters at implantation in patients with implantable cardioverter-defibrillator (ICD) and patients 
with cardiac resynchronisation therapy with defibrillation (CRT-D)
Parameter Patients with CRT-D therapy Patients with ICD therapy p value
Atrial lead pacing threshold 0.73 ± 0.59 0.34 ± 0.39 p < 0.05
Defibrillation lead pacing threshold 0.69 ± 0.2 0.66 ± 0.22 p > 0.05
Left ventricular lead pacing threshold 1.75 ± 1.71 None None
Atrial lead impedance 511.05 ± 271.30 280.03 ± 335.30 p < 0.05
Defibrillation ventricular lead impedance 547.13 ± 385.24 768.66 ± 210.62 p > 0.05
Left ventricular lead impedance 1,036.28 ± 337.34 None None
Table 3. Lead-associated electrical parameters at final follow-up in patients with implantable cardioverter-defibrillator (ICD) and patients 
with cardiac resynchronisation therapy with defibrillation (CRT-D)
Parameter Patients with CRT-D therapy Patients with ICD therapy p value
Atrial lead pacing threshold 0.67 ± 0.36 0.73 ± 0.27 p > 0.05
Defibrillation lead pacing threshold 0.97 ± 0.51 0.85 ± 0.26 p > 0.05
Left ventricular lead pacing threshold 1.71 ± 1.36 None None
Atrial lead impedance 388.55 ± 231.75 218.29 ± 229.48 p > 0.05
Defibrillation ventricular lead impedance 698.95 ± 165.45 507.03 ± 131.67 p > 0.05
Left ventricular lead impedance 794.87 ± 274.99 None None
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left bundle branch block (LBBB) [18, 19]. MacFadden et 
al. analysed 5,213 HF patients who received primary and 
secondary prevention ICDs for up to one year [20]. Of the 
921 women who received ICDs for primary prophylaxis, and 
the 367 who received ICDs for secondary prophylaxis, they 
found no difference in mortality between men and women. 
Myocardial scarring post-infarction is more often seen in 
men, and men with out-of- hospital sudden cardiac arrest 
are more likely to have VT/VF compared to women (41% 
vs. 30%). Women are more likely to have asystole (8.8% vs. 
7%) or pulseless electrical activity (24% vs. 18%) than men 
[21]. Women were more likely to have HF, non-ischaemic 
cardiomyopathy, and advanced NYHA class, and were 
more likely to receive CRT-defibrillators (CRT-D) compared 
to men [22]. In the MADIT-CRT trial, women demonstrated 
a lower mortality rate than men. Enina et al. [23] observed 
that the best response to CRT therapy is associated with 
female gender. In our population, men were eight times 
more likely to receive CRT-D implantation than women. 
Moreover, female pts presented with a higher LVEF than 
male pts [23].
We observed long-term stable pacing thresholds of atrial, 
defibrillation and left ventricular leads, but lead impedance 
varied at implantation as opposed to at final follow-up. The 
impedance increased with time in both ICD and CRT-D pts. 
Low impedance can be associated with insulation breaks, 
where a lead wire is exposed to a low resistance body fluid 
or another lead wire that induces a potential loss of capture 
or rapid battery depletion. Electrical dysfunction is usually 
related to a conducting wire fracture in cases of low-voltage 
circuits, where it can lead to oversensing, inappropriate 
shocks, and loss of capture. High-voltage circuit failure can 
lead to short circuiting with a failure to defibrillate [24]. In 
the literature, we found the devices most prone to failure to 
be Fidelis and Riata leads, 28% versus 15% respectively [25, 
26]. Data has indicated that an impedance threshold above 
100 ohm or an abrupt 75% increase in chronic impedance 
has identified a Fidelis fracture [27].
In CRT-D pts, primary prevention predominates, while in 
ICD pts primary and secondary prevention were balanced. 
The implantation of both ICD and CRT-D as primary and 
secondary prevention is associated with a decrease in the 
mortality rate [28–30].
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Streszczenie
Wprowadzenie. Wszczepialny kardiowerter-defibrylator (ICD) z terapią resynchronizującą (CRT-D) oraz bez niej stanowi 
efektywny element leczenia u pacjentów z niewydolnością serca.
Metody i wyniki. Sześćdziesięciu pacjentów (50/60; 83,33% mężczyzn) pozostających pod opieką kliniki kardiologii w la-
tach od maja 1995 roku do lutego 2019 roku z wszczepionym ICD/CRT-D, u których wykonano przynajmniej jedną wy-
mianę urządzenia, poddano retrospektywnej analizie. Kobietom rzadziej wszczepieniu zarówno ICD, jak i CRT-D niż męż-
czyznom (9/26 kobiet w grupie z ICD oraz 1/24 w grupie z CRT-D [p = 0,035], iloraz szans [OR] 8.31 95-proc. przedział 
ufności [CI] 0,98–70,56). Panie charakteryzowały się wyższą frakcją wyrzutową lewej komory (LVEF) (38,11 ± 12,74% 
v. 29,65 ± 12,63 [p = 0,027]). U opisywanych chorych CRT-D wszczepiano głównie w ramach w prewencji pierwotnej 
(22/25 v. 18/35 [p = 0,0726], OR 6,93 95% CI 1,75–27,43) oraz u pacjentów z niższą LVEF niż u osób z ICD (24,75 ± 
± 8,98 v. 35,52 ± 13,55%; p = 0,001). Analiza parametrów technicznych elektrod endokawitarnych wykazała obniżenie 
oporności, gdy porównano parametry z dnia wszczepienia i ostatniej wizyty kontrolnej. W grupie z wszczepionym ICD 
oporność elektrod przedsionkowych wynosiła 280,03 ± 335,3 w porównaniu z 218,29 ± 229,48 omów (p = 0,0018), 
a elektrod defibrylujących 768,66 ± 210,62 w porównaniu z 507,03 ± 131,67 omów (p < 0,001) (dzień implantacji 
v. ostatnia kontrola). W grupie poddanych CRT-D średnia oporność elektrod przedsionkowych wynosiła 511,05 ± 271,30 
w porównaniu z 388,55 ± 231,75 omów (p = 0,007), elektrod defibrylujących 698,95 ± 165,45 w porównaniu z 547,13 
± 385,24 omów (p = 0,002), a elektrod lewokomorowych 1036,28 ± 337,34 w porównaniu z 794,87 ± 274,99 omów 
(p < 0,001), gdy porównano dzień implantacji z dniem ostatniej kontroli.
Wnioski. Kobiety podlegają terapii resynchronizującej znacznie rzadziej niż mężczyźni. Ponadto CRT-D poddano pacjen-
tów z niższą LVEF, głównie w ramach prewencji pierwotnej. Oporność wszystkich elektrod ulegała obniżeniu z upływa-
jącym czasem.
Słowa kluczowe: terapia resynchronizująca, CRT, wszczepialny kardiowerter-defibrylator, ICD, niewydolność serca, 
oporność elektrod
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